GlassScriptPhysician profile
Carol M Ebersole
NPI 1720479850
$975.12
in general payments reported to CMS, 2019-2025
13 companies · $638 in 2025
The $638 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.58 · 2022: $91.72 · 2024: $208 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $233.79 | 2021-2025 | Nucala |
| Atricure, INC. | $129.49 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $100.72 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $97.97 | 2025 | |
| Csl Behring | $75.90 | 2025 | Hizentra, Andembry |
| Optinose US, INC. | $67.12 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $63.71 | 2025 | Dupixent |
| Amgen INC. | $58.67 | 2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $45.49 | 2025 | Cuvitru |
| Grifols USA, LLC | $39.17 | 2025 | Xembify |
| Genentech USA, INC. | $27.39 | 2021-2024 | Xolair |
| Biocryst US Sales Co., LLC | $21.48 | 2025 | Orladeyo |
| Pfizer INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Ebersole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.